Dexmedetomidine HCl - Moligand™,10mM in DMSO , Adrenergic receptor alpha-2 agonist, CAS No.145108-58-3, Adrenergic receptor alpha-2 agonist

CAS: 145108-58-3 Cat. No.: D409289 Molecular Weight: 236.74 EC Number: 682-047-2

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

5-​[(1S)​-​1-​(2,​3-​dimethylphenyl)​ethyl]​-​1H-​imidazole,hydrochloride (1:1)

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

Dexmedetomidine HCl is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant sedation.
In vitro

In vivo

Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Synonyms

5-​[(1S)​-​1-​(2, ​3-​dimethylphenyl)​ethyl]​-​1H-​imidazole, hydrochloride (1:1)

Specifications & Purity

Moligand™, 10mM in DMSO

Biochemical and Physiological Mechanisms

Dexmedetomidine HCl is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant sedation.

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

AGONIST

Mechanism of action

Adrenergic receptor alpha-2 agonist

Names and Identifiers

• Isomeric SMILES: CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C.Cl
• WGK Germany: 3
• RTECS: NI5156750
• Molecular Weight: 236.74
• Reaxy-Rn: 5362300
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=5362300&ln=

Chemical and Physical Properties

• Solubility: Solubility (25°C) In vitro Water: 34 mg/mL (198.65 mM); DMSO: 7 mg/mL (40.89 mM); Ethanol: Insoluble
• Specific Rotation[α]: 51° (C=1,H2O)
• Melt Point(°C): 158 °C

References

1. Kaiyu Xu, Ying Zhang, Yongxuan Chen, Xiaojia Zhu, Yu Li, Longbao Lv, Xiechao He, Zhengfei Hu, Yifan Li, Maosen Ye, Dewei Jiang, Zhanlong He, Weihua Jin, Yanyan Li, Xiaomei Yu, Deng-Feng Zhang, Karl Herrup, Ping Zheng, Yong-Gang Yao, Dong-Dong Wu, Jiali Li.  (2025)  ATM deficiency drives phenotypic diversity and Purkinje cell degeneration in a macaque model of ataxia-telangiectasia.  Cell Reports Medicine,      [PMID:40961921] [10.1016/j.xcrm.2025.102355]

2. Qiuxia Liao, Zhi Feng, Hairong Lin, Ye Zhou, Xinxin Lin, Xiao Lin, Huichang Zhuo.  (2025)  Dexmedetomidine improves septic acute kidney injury by inhibiting inflammation and oxidative stress through the activation of the Pink1/Park2 autophagy pathway.  RENAL FAILURE,      [PMID:40485166] [10.1080/0886022X.2025.2513677]

3. Ce Wu, Di Wu, LiJie Xie, HouYong Yan, Wei Zhang, Fei Yu.  (2026)  Near-Infrared Responsive Injectable Thermosensitive Hydrogel Sequentially Releases Dexmedetomidine and Ropivacaine for Postoperative Pain Management.  COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS,      [PMID:] [10.1016/j.colsurfa.2026.139503]